1. Organization and Business History and Organization We were incorporated on December 20, 2010 in the State of Nevada as Accend Media. On May 23, 2012 we consummated a merger (the Merger) with Cloud Star Corporation, a Nevada corporation, and we changed our name to Cloud Star Corporation (Cloud Star). The Merger was accounted for as a reverse acquisition with Cloud Star being treated as the acquirer for accounting purposes. On May 28, 2013, we changed our corporate name from Cloud Star Corporation to Cloud Security Corporation. On December 8, 2014, we entered into a Stock Purchase Agreement (the Goldenrise Agreement) with Goldenrise Development, Inc. (Goldenrise). Under the Goldenrise Agreement, we sold 12,000,000 shares of our common stock to Goldenrise for $180,000 which equated to approximately 92% of our outstanding shares. This transaction effectuated a change in control of our Company. On June 28, 2017, Goldenrise and our Company entered into a Stock Purchase Agreement (the Dunn Agreement) with Michael R. Dunn, our then sole officer and director (Dunn). Pursuant to Dunn Agreement, Goldenrise agreed to sell 12,000,000 shares of our common stock to Dunn representing approximately 92% of our outstanding shares. In consideration for these shares, Dunn agreed to pay Goldenrise a total of $400,000 as follows: (i) $180,000 on or before July 15, 2017 (extended to July 28, 2017), (ii) $180,000 withheld as an offset to monies owed by Goldenrise to Dunn; and (iii) $40,000 withheld and applied towards invoices related to the audit and legal fees associated with the reporting requirements of our Company through the date of Closing. Concurrently, on June 28, 2017, Dunn entered into a Stock Purchase Agreement (the SPA) with China Israel Biotechnology Co. Ltd. (China-Israel) and Central Bio-MD Technology Co. Ltd. , each a Chinese corporation (collectively, the Buyers or China-Israel). Pursuant to the SPA, Dunn agreed to sell 6,000,000 of our common shares, representing approximately 46% of our outstanding shares. In consideration for the shares, Buyers agreed to pay Dunn a total of $200,000 upon the SPAs execution (the Purchase Price). The Closing for both the Dunn Agreement and the SPA occurred on July 28, 2017. The Dunn Agreement and the SPA resulted in a change in control of our Company. On December 29, 2017, our Board of Directors approved an agreement and plan to merge with our wholly-owned subsidiary, US-China Biomedical Technology, Inc., a Nevada corporation, to effectuate a name change from Cloud Security Corporation to US-China Biomedical Technology, Inc. (US-China). US-China was formed solely for the purpose of this name change and our Company was the surviving entity following the merger. On February 8, 2018, the Financial Industry Regulatory Authority (FINRA) announced the effectiveness of a change in our Companys name to US-China Biomedical Technology, Inc. and new trading symbol UCBB which became effective on the opening of trading as of February 9, 2018. Business We are an early stage biomedical technology and services company. Through late 2017 our principal business was related to the software development of MyComputerKey and our other patented cloud computing technologies; however, due to cash flow constraints, we were unable to proceed with the further development of our software. Due to enhanced competition in the software development market and advancements in technology made by our competitors, we began evaluating alternative business plans. Following the change in control of our Company pursuant to the SPA, we decided to put the software development on hold and shift our primary business focus. Our immediate business focus is directed at the marketing and sales in the United States of unique products and technology developed by BSP Medical Ltd. (BSP), an affiliate company headquartered in Israel. BSP is a biomedical technology company revolutionizing non-invasive diagnosis of cardiac diseases. BSP offers a range of electrocardiogram (ECG) products based on the HyperQ technology. These include complete systems for routine clinical use, research-oriented systems, and original equipment manufacturer (OEM) products. Research systems facilitate data analysis by exporting all test parameters and measurements in a configurable format via a web based user-friendly interface. We have begun identifying qualified physicians and additions to our management team to begin initiation of operations in the US in order to begin sales and marketing of the BSP products in the US market. In addition, we are in the process of developing a joint venture with BSP whereby we will market and sell certain of their products. One BSP product of interest is the HyperQ Analyzer Stress, a unique software module designed to analyze Stress Test ECG based on the detection of changes in the high frequency component of the QRS segment. HyperQ can be integrated in any ECG stress systems. Another product is the HyperQ Analyzer Rest which is an innovative software module for early detection of acute coronary artery disease on any ECG rest systems. It provides a new perspective to the clinical staff, in particular diagnosis of Non-ST Elevation MI (NSTEMI) and Unstable Angina (UA). A secondary aspect of our plan is the integration and development of synergistic relationships with high profiled doctors and hospitals that will act as a bridge for connecting patients and bio-technology advances in China with our Companys network of US based doctors and hospitals. We intend to develop a scalable biomedical bridge for the US and China markets. We will provide services for moving patients from China to the US with an emphasis on the following demographics: (i) cancer patient referrals that are in non-critical, non-life-threatening positions, (ii) pre-screening and genetic testing for family members of cancer patients, (iii) patients suffering from Diabetes, and (iv) general medical services including preventative care and physicals. We also intend to develop working relationships with key medical innovators for possible joint ventures related to medical device manufacturing in China, including working towards obtaining China Food &amp; Drug Administration (CFDA) approval for medical device sales to government owned hospitals. As of the date of this report, we have begun identifying qualified physicians and additions to our management team to begin initiation of operations in the US. The business plan is currently in the development phase. Matters Relating to Former Officers and Directors On November 23, 2017, our former Chief Executive Officer and Director, Michael R. Dunn, passed away unexpectedly. On January 9, 2018, Ms. Amanda Huang resigned as the Senior Vice President of our Company effective immediately. Our board of directors (Board) approved and accepted Ms. Huangs resignation as Senior Vice President on January 10, 2018. On July 17, 2018, our Board appointed Dr. H. Rand Scott (Dr. Scott) as a member of Board and on January 3, 2019, Dr. Scott resigned from this position. The resignation was not the result of any disagreement with our Company on any matter relating to our Companys operations, policies, or practices. On March 20, 2019, our Board appointed Mr. Safa Movassaghi (Mr. Movassaghi) as a member of our Board. Concurrently, Mr. Movassaghi resigned from his role as Vice President, a role to which he was appointed on November 6, 2018. Mr. Movassaghis resignation has a retroactive effective date of February 28, 2019. The resignation was not due to any disagreement with our Company, its policies or practices.